Skip to Main Content

Paper Details

Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.
Contemp Clin Trials
48
2016
Ibudilast, MS, PMS, Primary and secondary progressive multiple sclerosis, cortical brain atrophy, ibudilast, macrophage migration inhibitor factor, multiple sclerosis, neurologic disability, patient, patients, phosphodiesterases-4 and -10, progressive multiple sclerosis, retinal nerve fiber, whole brain atrophy
Author NameAffiliation
Christopher S CoffeyUniversity of Iowa
Robin ConwitNational Institutes of Neurological Disease and Stroke
Dixie EcklundUniversity of Iowa
Michael K RackeThe Ohio State University
Shlomo ShinnarMontefiore Medical Center
  • 1 - 5

Datasets

Release 1.2